Submitted:
23 February 2023
Posted:
27 February 2023
Read the latest preprint version here
Abstract
Keywords:
Introduction
Material and Methods
Results
Discussion
Conclusion
AUTHORS’ CONTRIBUTION
CONFLICT OF INTEREST ESTATEMENT
ACKNOWLEDGMENT
-
Tatiane Lobato da Silva.Health and Biological Centre, State of Pará University, 2623 Perebebui St,Belem, Pará 66087-670, Brazil.
-
Apio Ricardo Nazareth Dias.Health and Biological Centre, State of Pará University, 2623 Perebebui St,Belem, Pará 66087-670, Brazil.
-
Juarez Antônio Simões Quaresma.Health and Biological Centre, State of Pará University, 2623 Perebebui St,Belem, Pará 66087-670, Brazil.Tropical Medicine Centre, Federal University of Pará, 92 GeneralissimoDeodoro Ave, Belém, Pará 66055-240, Brazil
-
Luiz Fábio Magno FalcãoHealth and Biological Centre, State of Pará University, 2623 Perebebui St,Belem, Pará 66087-670, Brazil.University of São Paulo, 455 Dr Arnaldo Ave, São Paulo, São Paulo 01246-903, Brazil
References
- Mbituyumuremyi A, Van Nuil JI, Umuhire J et al. Controlling hepatitis C in Rwanda: a framework for a national response. Bull World Health Organ. 2018, 96, 51–8. [Google Scholar] [CrossRef]
- Piselli P, Serraino D, Fusco M et al. Hepatitis C virus infection and risk of liver-related and non-liver-related deaths: a population-based cohort study in Naples, southern Italy. BMC Infect Dis. 2021, 21, 667. [Google Scholar] [CrossRef] [PubMed]
- World Health Organization, Hepatitis C, Hepatitis C key facts, World Health Organization Media Centre, Geneva, Switzerland, 2022, https://www.who.int/news-room/fact-sheets/detail/hepatitis-c.
- Brazil Ministry of Health, 2021 Epidemiological Bulletin on Viral Hepatitis, Health Surveillance Secretariat, Department of STD, AIDS and Viral Hepatitis, Ministry of Health, Brasília, Brazil, 2021 (Portuguese), http://www.aids.gov.br/pt-br/pub/2021/boletimepidemiologico-hepatites-virais-2021.
- Westbrook RH, Dusheiko G. “Natural History of Hepatitis C.” Journal of Hepatology. 2014, 61, S58–S68.
- Motawi TMK, Sabry D, Shehata NI, et al. Impact of FOXP1 rs2687201 genetic variant on the susceptibility to HCV-related hepatocellular carcinoma in Egyptians. J Biochem Mol Toxicol. 2021, 16, e22965. [Google Scholar]
- Yousaf A, Ghafoor A, Fátima N, et al. Gender-specific frequency distribution of hepatitis C virus genotypes in Punjab Province, Pakistan: a clinically significant cross-sectional study. Cureus. 2021, 13, e17480. [Google Scholar]
- Wang B, Krüger L, Machnowska P, et al. Characterization of a hepatitis C virus genotype 1 divergent isolate from an HIV-1 coinfected individual in Germany assigned to a new subtype 1o. Virol J. 2019, 16, 2803–04.
- Strauss, E. Natural History of Hepatitis C - Progression Factors. Prognostic assessment of chronic hepatitis C. Treatise on Viral Hepatitis and Associated Diseases. São Paulo: Atheneu. 2013: 453-470.
- Cheng XD, Xu HF, Wei F, et al. Genotype analysis of hepatitis C virus in Heilongjiang Province, China. Medicine. 2021, 100, e25203. [Google Scholar] [CrossRef]
- Codeço CT, Dal’Asta AP, Rorato AC. et al. Epidemiology, Biodiversity, and Technological Trajectories in the Brazilian Amazon: From Malaria to COVID-19. Front Public Health. 2021, 13, 647754. [Google Scholar] [CrossRef]
- Alves de Oliveira, BF, Bottino, MJ, Nobre, P. et al. Deforestation and climate change are projected to increase heat stress risk in the Brazilian Amazon. Commun Earth Environ. 2021, 2. [Google Scholar] [CrossRef]
- Azhar MJ, Khalid N, Azhar S, et al. Study of the Effect of Different Hepatitis C Virus Genotypes on Splenomegaly. Cureus. 2020, 3112, e10164. [Google Scholar]
- Fonseca JCF, Brazil LM. Hepatitis C virus infection in the Brazilian Amazon region. Rev. Soc. Bras. Med Trop. 2004, 37, 1–8. [Google Scholar]
- Nicolau S, Medeiros AS, Santos MCA, Montarroyos JS. Epidemiological profile of hepatitis B in a regional health center in Recife, Rev. Saúde Col. UEFS. 2017, 7, 30–35. [Google Scholar]
- Moia LJMP, Amaral ISA, Farias AJL, Silva MMA. Hepatitis C virus infection in a referral hospital in the Brazilian Amazon. Rev Para Med. 2014, 28, 19–25. [Google Scholar]
- Suarez-Kurtz G, Paula DP, Struchiner CJ. Pharmacogenomic implications of population admixture: Brazil as a model case. Pharmacogenomics. 2014, 15, 209–219. [Google Scholar] [CrossRef]
- Salzano FM and Sans, M. Interethnic admixture and the evolution of Latin American populations. Genetics and Molecular Biology 2014, 37, 151–170. [Google Scholar] [CrossRef]
- Sá LC, Araújo TME, Griep RH, Campelo V, Monteiro CFS. Hepatitis C seroprevalence and associated factors in crack users. Rev Latinoam Enferm. 2013, 21, 1195–202. [Google Scholar] [CrossRef]
- Confalonieri UEC, Margonari C, Quintão AF. Environmental change and the dynamics of parasitic diseases in the Amazon. Acta Tropica. 2014, 129, 33–41. [Google Scholar] [CrossRef]
- Sawada L, Pinheiro ACC, Locks D, et al. Distribution of hepatitis C virus genotypes among different exposure categories in the State of Pará, Brazilian Amazon. Rev. Soc. Bras. Med. Trop. 2011, 44, 8–12. [Google Scholar] [CrossRef] [PubMed]
- Guimaraes VS, Melo TG, Ferreira RCD, Almeida SF, Martins LC. Prevalence of hepatitis C virus genotypes in the State of Pará, Brazil. Rev. Soc. Bras. Med. Trop. Uberaba 2018, 51, 508–512. [Google Scholar] [CrossRef] [PubMed]
- 23. Barbosa KMV, Moreira LVL, Oliveira CMA, et al. Hepatitis C in the 1980s: rescue of old “non-A and non-B” hepatitis cases from a hepatology service in the Amazon, Brazil. 2019. Rev Pan Amaz Saude 2019; 10:1-11.
- Olmedo G, Nagai M, Sugastti AL, et al. Epidemiological and molecular characterization of Hepatitis C in the population that went to the Central Laboratory of Public Health, Paraguay 2013-2018. Rev. public salud Parag. 2019, 9, 73–80. [Google Scholar] [CrossRef]
- Santos Ó, Gómez A, Vizcaíno V, Casas MC, Ramírez MDP, Olaya P. [Hepatitis C virus genotypes circulating in Colombia]. Biomedica. 2017 Jan 24; 37:22-27.
- Duran A., Ç. , Çetinaka ÖK, Sayiner AA, et al. Changes on Hepatitis C virus genotype distribution in Western Turkey: Evaluation of twelve-year data. Turk J Gastroenterol 2020, 31, 128–135. [Google Scholar] [CrossRef]
- Døssing A, Røge BT, Madsen LG, et al. Hepatitis C virus elimination in Denmark. Ugeskr Laeger. 2020, 182, v08190481. [Google Scholar]
- Petruzziello A, Sabatino R, Loquercio G, et al. Nine-year distribution pattern of hepatitis C virus (HCV) genotypes in Southern Italy. PLoS One. 2019, 14, e0212033. [Google Scholar]
- Bruno S, Crosignani A, Maisonneuve P, Rossi S, Silini E, Mondelli MU. Hepatitis C virus genotype 1b as a major risk factor associated with hepatocellular carcinoma in patients with cirrhosis: a seventeen-year prospective cohort study. Hepatology. 2007, 46, 1350–1356. [Google Scholar] [CrossRef] [PubMed]
- Kermani FR, Sharifi Z, Ferdowsian F, Paz Z, Zamanian M. Distribution of hepatitis C virus genotypes among chronic infected injecting drug users in Tehran, Iran. Jundishapur J Microbiol. 2013, 6, 265–268. [Google Scholar]
- Carnaúba LAB, Pontes LR, Flavio LF, et al. Hepatitis C staging: elastography compared with liver biopsy. Cad. Med. UNIFESO. 2018, 1, 111–123. [Google Scholar]
- Franco, KMV, Vieira WB, Dias ARN, et al. Doppler ultrasound: a non-invasive method used to diagnose and monitor patients with chronic hepatitis C. Journal of Gastroenterology and Hepatology. 2019; 35.
- Lutz H, Gassler N, Tischendorf F, Trautwein C, Tischendorf J. Doppler ultrasound of liver blood flow for noninvasive assessment of liver fibrosis compared with liver biopsy and transient elastography. Excavation. Dis. Sci. 2012, 57, 2222–2230. [Google Scholar] [CrossRef] [PubMed]
- Fahmy MI, Badran HM. Comparison of transient elastography with Doppler indices in predicting hepatitis C-induced liver fibrosis and cirrhosis. The Egyptian J. Radio. Nucl. Med. 2011, 42, 111–117. [Google Scholar] [CrossRef]
- Mello FSF, Lima JMDC, Hyppolito EB, et al. Comparison of hepatic fibrosis degrees in chronic hepatitis C (HCC) measured by elastography and serology methods: ARFI and Fibroscanvs APRI and FIB4. Rev. Med. UFC. 2020, 60, 18–25. [Google Scholar]
| SOCIODEMOGRAPHIC PROFILE | n | % | P-Valor (1) |
|---|---|---|---|
| AGE | |||
| Up to 59 years old | 35 | 46.1% | 0.491ns |
| > 60 years old | 41 | 53.9% | |
| Sex | |||
| Men | 51 | 67.1% | 0.004* |
| Women | 25 | 32.9% | |
| COLOR/RACE | |||
| White | 12 | 15.8% | 0.000* |
| Black | 8 | 10.5% | |
| Dark-skinned | 56 | 73.7% | |
| SCHOOLING | |||
| Up to 9 years of study | 31 | 40.8% | 0.136ns |
| > 9 years of study | 45 | 59.2% | |
| Incomplete/complete higher education | 0 | 0.0% | |
| MUNICIPALITY OF RESIDENCE | |||
| Abaetetuba | 71 | 93.4% | 0.000* |
| Others | 5 | 6.6% | |
| AREA OF RESIDENCE | |||
| Rural area | 11 | 14.5% | 0.000* |
| Urban area | 65 | 85.5% | |
|
OCCUPATION Retired |
29 | 38.2% | 0.051ns |
| Active work | 47 | 61.8% | |
| MARITAL STATUS | |||
| Married / Stable union | 53 | 69.7% | 0.001* |
| Single/ Widower | 23 | 30.3% | |
| POSSIBLE FORM OF TRANSMISSION | |||
| Surgical | 43 | 56.6% | 0.000* |
| Blood transfusion (Parenteral route) | 46 | 60.5% | |
| Sexual Route | 3 | 3.9% | |
| Not informed | 20 | 26% | |
| CLINICAL FORM | |||
| Acute | 4 | 5.3% | 0.000* |
| Chronicle | 53 | 69.7% | |
| Not filled | 19 | 25.0% | |
| CLINICAL PROFILE | n | % | p-value (1) |
|---|---|---|---|
| FIBROSIS CLASSIFICATION | |||
| F0 | 8 | 10.5% | 0.140ns |
| F1 | 14 | 18.4% | |
| F2 | 15 | 19.7% | |
| F3 | 8 | 10.5% | |
| F4 | 13 | 17.1% | |
| Exam not performed | 14 | 18.4% | |
| Exam performed/not valid measures | 4 | 5.3% | |
| ELASTOGRAPHY (RESULT IN KPA) | |||
| 1.2-6.2 | 11 | 14.5% | 0.000* |
| 6.2-11.2 | 32 | 42.1% | |
| 11.2-16.2 | 6 | 7.9% | |
| 16.2 ou mais | 9 | 11.8% | |
| GENOTYPE OF HEPATITIS C VIRUS | |||
| 1 | 42 | 55.3% | 0.001* |
| 2 | 2 | 2.6% | |
| 3 | 22 | 28.9% | |
| HEPATITIS C VIRUS SUBGENOTYPE | |||
| 1a | 10 | 13.2% | 0.000* |
| 1b | 32 | 42.1% | |
| 3a | 1 | 1.3% | |
| Not Subtyped | 10 | 13.2% | |
| Genotypes/Subgenotypes |
F0 (n = 8) |
F1/F2 (n = 27) |
F3/F4 (n = 20) |
p-value (1) | |||
| n | % | n | % | n | % | ||
| Hepatitis C virus genotype | |||||||
| 1 | 5 | 62.5% | 15 | 55.6% | 16 | 80.0% | 0.607ns |
| 2 | 0 | 0.0% | 1* | 3.7% | 0 | 0.0% | |
| 3 | 3 | 37.5% | 11 | 40.7% | 4 | 20.0% | |
| Hepatitis C virus subgenotype |
F0 (n = 5) |
F1/F2 (n = 15) |
F3/F4 (n = 20) |
||||
| 1a | 3 | 60.0% | 4 | 26.7% | 3 | 15.0% | 0.002* |
| 1b | 2 | 40.0% | 9 | 60.0% | 15 | 75.0% | |
| 3a | 0 | 0.0% | 0 | 0.0% | 1 | 5.0% | |
| Not subtyped | 0 | 0.0% | 2 | 13.3% | 1 | 5.0% | |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
